AstroNova is at critical inflection point in its strategic progress to create meaningful competitive advantages for the Product Identification segment and drive strong, sustainable growth, improved profitability and address measurably larger addressable markets Askeladden/Patel's misguided, upstart campaign is disrupting progress and his unfit nominees stand to siderail advancement Urges shareholders to vote "FOR" ONLY AstroNova's Board nominees on the WHITE proxy card Current leadership has transformed AstroNova's capabilities, product mix, and scale, delivering 7.5% compound annual revenue growth since Gregory Woods' appointment as CEO AstroNova, Inc. (NASDAQ:ALOT), a leading innovat

The IDS i20 platform offers fully automated processing of specialty assays in endocrinology, allergy, autoimmune and infectious diseases, Alzheimer's disease and therapeutic drug monitoring Revvity, Inc. (NYSE:RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 instrument allows users to simultaneously ru

Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2025 9:20 a.m. PT - Max Krakowiak, senior vice president and chief financial officer Goldman Sachs 46th Annual Global Healthcare Conference Tuesday, June 10, 2025 8:00 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will b

Revenue of $665 million; 2% reported growth; 4% organic growth GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01 Reaffirms full year 2025 organic growth and adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operating profit margin from continu

The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detec

Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows

FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases Revvity, Inc. (NYSE:RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U

New agreement to support newborn health adds sequencing lab services to the existing extraction services collaboration Revvity, Inc. (NYSE:RVTY) today announced an agreement with Genomics England to further collaborate on the Generation Study. Under the new contract, Revvity will now also provide DNA sequencing services to help screen newborns for rare genetic conditions. This expanded relationship builds upon the previously disclosed agreement to perform DNA extraction services. Revvity will now be able to provide an integrated end-to-end solution with a localized lab facility, which will allow for accelerated extraction and sequencing services to advance the screening process for these r

Company expands infectious disease diagnostics portfolio with first of several assays validated for dried blood spots as sample material Revvity, Inc. (NYSE:RVTY), today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN's Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN's serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to serum and plasma. Measles is a highly contagious airborne disease that can lead to severe compli

Today, Revvity, Inc. (NYSE:RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rights under its agreements with Cloud Software Group (CSG) related to the Spotfire® software. This ruling follows a preliminary injunction issued in April 2024, which will become permanent, ensuring uninterrupted access to Spotfire software and support for Revvity and its customers, protecting operational continuity and service quality. "We are pleased with the court's decision upholding our agreements and the commitments made to our customers," said Kevin Willoe, SVP and general manager at Revvity Signals Software. "This rulin

SC 13G/A - REVVITY, INC. (0000031791) (Subject)

SC 13G/A - REVVITY, INC. (0000031791) (Subject)

SC 13G - REVVITY, INC. (0000031791) (Subject)

SC 13G/A - REVVITY, INC. (0000031791) (Subject)

UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

Barclays upgraded Revvity from Equal Weight to Overweight and set a new price target of $140.00 from $125.00 previously

Wells Fargo initiated coverage of Revvity with a rating of Equal Weight and set a new price target of $130.00

Leerink Partners initiated coverage of Revvity with a rating of Outperform and set a new price target of $125.00

Jefferies resumed coverage of Revvity with a rating of Hold and set a new price target of $115.00

UBS downgraded Revvity from Buy to Neutral and set a new price target of $125.00 from $105.00 previously

Evercore ISI upgraded Revvity from In-line to Outperform and set a new price target of $125.00 from $88.00 previously

Wells Fargo initiated coverage of Revvity with a rating of Equal Weight and set a new price target of $95.00

10-Q - REVVITY, INC. (0000031791) (Filer)

8-K - REVVITY, INC. (0000031791) (Filer)

8-K - REVVITY, INC. (0000031791) (Filer)

DEFA14A - REVVITY, INC. (0000031791) (Filer)

DEF 14A - REVVITY, INC. (0000031791) (Filer)

S-3ASR - REVVITY, INC. (0000031791) (Filer)

PRE 14A - REVVITY, INC. (0000031791) (Filer)

10-K - REVVITY, INC. (0000031791) (Filer)

SCHEDULE 13G/A - REVVITY, INC. (0000031791) (Subject)

144 - REVVITY, INC. (0000031791) (Subject)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)